B. Riley analyst Mayank Mamtani lowered the firm’s price target on Harrow (HROW) to $65 from $74 and keeps a Buy rating on the shares. The firm’s FY26 revenue estimate is cut to $352M from $459M, but it calls this a “timing-driven downward revision, not demand-driven.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HROW:
- Harrow price target lowered to $65 from $74 at B. Riley
- Harrow Health Expands Senior Notes Offering for Growth
- Harrow Health Prices $50 Million Senior Notes Offering
- Opportunistic Capital Strategy and Iheezo Growth Opportunities Support Harrow Health Buy Rating
- Harrow Health Announces $50 Million Senior Notes Offering